NCT02407080View on ClinicalTrials.gov

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 19, 2018

Study Completion Date

December 19, 2018

Conditions
Polycythemia VeraEssential Thrombocythemia
Interventions
DRUG

RG7388

RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.

DRUG

Pegasys

PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously

Trial Locations (3)

10029

Icahn School of Medicine at Mount Sinai, New York

20007

Georgetown University Medical Center, Washington D.C.

27157

Wake Forest University Baptist Medical Center, Winston-Salem

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

The Leukemia and Lymphoma Society

OTHER

lead

John Mascarenhas

OTHER

NCT02407080 - Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | Biotech Hunter | Biotech Hunter